TriNutra has been granted a US patent for products that combine ThymoQuin and astaxanthin with other biologically active compounds.
According to the new patent, the pairing demonstrated "synergistic biological activity," supporting enhanced efficacy compared to the individual ingredients alone.
TriNutra is a major producer of premium USP black seed oil brands, of which Thymoquinone is a key bioactive compound.
Clinical research has supported the ingredient in supporting healthy cortisol levels and the gut microbiome, as well as promoting better mood and sleep, healthy blood pressure and antioxidant protection.
However, the substance is unstable in the presence of oxidants (such as free fatty acids), leading to decreased potency and diminished stability of black seed oil.
TriNutra develops technologies to standardise, stabilise and maintain the natural balance of bioactive compounds in its black seed oil products.
The company produces its ThymoQuin ingredient through a strict growing, harvesting and proprietary cold-press manufacturing process, resulting in a unique composition that balances thymoquinone, p-cymene and free fatty acids (FFAs).
"Our unique formulation approach continues to demonstrate that the composition of black seed oil's bioactives matters significantly," said Morris Zelkha, CEO of TriNutra.
ThymoQuin has brought innovation to this ancient ingredient with several published clinical trials on its health benefits and composition-dependent efficacy and numerous global patents back it for its composition, stability, bioavailability and use.
"We are incredibly proud of yet another achievement for ThymoQuin and its potential in health and wellness.”
Astaxanthin is known for its potential to support a healthy inflammatory response, cognitive function, cardiovascular health, mood states and more.
TriNutra’s published research, which it said led to the application for this patent, demonstrated that the pairing had a synergistic effect, potentiating astaxanthins' inflammatory activity.
Zelkha continued: "ThymoQuin was specifically developed to preserve and optimise the key bioactives found in black seed oil and our research found that pairing it with astaxanthin resulted in synergistic biological activity, particularly in supporting a balanced inflammatory response and antioxidant protection."
The patent award follows the publication of clinical research demonstrating that ThymoQuin significantly reduced cortisol levels while improving sleep quality and stress resilience in moderately stressed adults, as well as further research on ThymoQuin-OCare for oral health, which showed improvements in gingival function, plaque accumulation and oral microbiome diversity.
